Logo

American Heart Association

  2
  0


Final ID:

Evolution of Novel Therapies in Vascular Medicine

  • Creager, Mark  ( Dartmouth-Hitchcock , Lebanon , New Hampshire , United States )
  • Beckman, Joshua  ( UT Southwestern , Dallas , Texas , United States )
  • Author Disclosures:
    Mark Creager: DO NOT have relevant financial relationships | Joshua Beckman: DO have relevant financial relationships ; Consultant:Janssen:Past (completed) ; Consultant:Merck:Active (exists now) ; Consultant:Antidote Therapeutics:Active (exists now) ; Consultant:Mingsight:Active (exists now) ; Consultant:JanOne:Active (exists now) ; Consultant:Novartis:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Featured Science: Vascular Outcomes in the Spotlight

Monday, 11/18/2024 , 08:00AM - 09:15AM

Featured Science

More abstracts on this topic:
Anatomically Directed Lower Extremity Gene Therapy for Ulcer Healing: A Double Blind, Randomized, Placebo Controlled Study

Armstrong David, Farber Alik, Zelen Charles, Powell Richard, Conte Michael, Mills Joseph, Menard Matthew, Orgill Dennis, Galiano Robert, Kirsner Robert, Hicks Caitlin, Lantis John

Rivaroxaban for 18 Months versus 6 Months in Cancer Patients with Low-risk Pulmonary Embolism: ONCO PE Trial

Yamashita Yugo, Morimoto Takeshi, Muraoka Nao, Shioyama Wataru, Chatani Ryuki, Shibata Tatsuhiro, Nishimoto Yuji, Ono Koh, Kimura Takeshi

More abstracts from these authors:
You have to be authorized to contact abstract author. Please, Login
Not Available